Grade ≥ 3 peripheral neuropathy occurred in 13.7% of patients receiving the ABCP regimen, whereas no cases were observed in the ACnP group, underscoring the higher risk of severe neurotoxicity associated with ABCP. Here, ABCG2 is linked to peripheral neuropathy.